Tron Logo
Trade on HitBTC
Like this video

Ratings Dermavir

Dendritic Cell-Targeting Therapeutic Vaccine

We are a privately held clinical-stage biotechnology company focusing on the development and commercialization of a revolutionary new immune therapy platform for the treatment of chronic viral infections, cancer and allergy. Our technology is designed to boost specific immune response in order to modify or control presently incurable diseases. Our proprietary Vaccine Platform includes a given disease’s antigen specific plasmid DNA (pDNA), a nanomedicine formulation which encapsulates the pDNA to make it closely resemble a virus (we call this combination a nanoparticle), a topical (through the skin) administration device we call DermaPrep which delivers the vaccine via dendritic cell to lymph nodes of the immune system, and a software product which allows us to design antigen specific pDNA and closely match it to a patient’s genetic and HLA profile. The combination of these technologies supports the rapid and cost-effective development of original biologic vaccine products.

2.9
4 3 expert ratings
Benchy 2.6
KYC
Experts
3.0
5.0
2.2
Review: coming soon PRO
Unknown
Token
DER
Type
PreICO Price
1 DER = 0.70 USD
Price
1 DER = 1 USD
Bonus
Available
Platform
Accepting
ETH
Minimum investment
0.1 ETH
Hard cap
10,000,000
Country
USA
Whitelist/KYC
KYC
Visit ICO website
Report

Ratings

All ratings published on ICObench serve informational purposes only. ICObench does not provide investment forecast, recommendations or any consulting for that matter. Thus, neither ICObench, nor the experts can be hold responsible for the visitors’ investment decisions. Read more
James Sowers
Ico adviser
Rated on Mar 29, 2018
Modified on Oct 10, 2018
3
5
2
23%

Great project helping man kind vaccinate HIV
Looks like it didn’t pan out best of luck to them in this ambitious project hopefully one day they help mankind

Agree
0
Disagree
Report
Manav Singhal
Executive Board Member at Blockchain Foundation of India
Rated on Apr 9, 2018
5
5
5
6%
This rating's weight is reduced by 50% as there is no review added.
Arthur Zubkoff
FinTech & Marketing Consultant
Rated on Apr 12, 2018
2
5
1
11%

Pros:
+ Idea of Vaccine-to-Virus matching on Blockchain
+ Detailed whitepaper
+- Comprehensive distribution

Cons:
- Small team and lack of advisors in the industry
- No online product (apart from DermaVir which is an experimental vaccine), no one-pager, limited website, poor media presence
- Lots of emerging competitors in healthcare; licensing & regulation

Agree
0
Disagree
Report
Benchy
ICO analyzer bot
2.6
59%

Experts are independently and voluntarily contributing to the community. If no expert has rated the ICO, only ICO analyzer's results are used. Always research before investing as these ratings should not be taken as an investing guide of any kind.

Ratings and ICO analyzer results are being updated (re-calculated) every few hours.

Add to bookmarks
ICO KYC Report
Not conducted yet
KYC procedure verifies selected/specific team members only. It does not guarantee ICO success nor is a call for investment.
Missing or incorrect data? Let us know.

ICOs that might interest you

WINSSHI

Winsshi is the world's first decentralized gaming platform with revenue sharing module.

68 days 22 hours left
4.7

PointPay

First Worldwide Working Crypto Bank Ready and Live, Live Working Fiat Exchange, Live Wo...

99 days 12 hours left
4.4

QUASA

First Open Blockchain Platform With Artificial Intelligence For Connecting People Revo...

4.5

Mindsync

Mindsync is a platform to solve customer's tasks with AI technologies competitions as w...

69 days 12 hours left

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Learn more Got it